Advertisement


David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery

2021 ASTRO Annual Meeting

Advertisement

David A. Palma, MD, PhD, of Ontario’s London Health Sciences Centre, discusses results of the ORATOR2 study, which compared two treatment options that could be de-escalated for patients with HPV-associated oropharyngeal squamous cell carcinoma: a lower-dose radiation approach (6 weeks instead of 7, often with chemotherapy) vs a transoral surgical approach (with low-dose radiation afterward, for 5 weeks) (Abstract LBA2).



Related Videos

Head and Neck Cancer

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

Daniel J. Ma, MD, of the Mayo Clinic Alix School of Medicine, discusses results from a phase III study of patients with HPV-associated oropharyngeal squamous cell carcinoma. Comparing a 2-week course of de-escalated adjuvant radiation therapy with the standard 6-week course, investigators found that the shorter treatment appeared to have less toxicity, higher quality of life, and similar disease control as the longer standard-of-care treatment (Abstract LBA1).

Breast Cancer
Immunotherapy
Symptom Management

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Treatment-Related Cardiotoxicity

Youssef Zeidan, MD, PhD, of Florida International University and the Lynn Cancer Institute, discusses the advances in radiotherapy planning and delivery that have reduced cardiac radiation exposure in patients with HER2-positive breast cancer who are treated with radiotherapy and trastuzumab (Abstract 12).

CNS Cancers
Genomics/Genetics

Diana D. Shi, MD, on IDH-Mutant Gliomas: De Novo Pyrmidine Synthesis Inhibitor Under Study

Diana D. Shi, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Cancer Center, discusses studies being planned and already underway to test BAY 2402234, a de novo pyrimidine synthesis inhibitor that possibly could be used clinically to target IDH-mutant gliomas and may act as a tumor-selective radiosensitizer (Abstract 167).

Breast Cancer

Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial

Yongbae Kim, MD, of the Yonsei Cancer Center and Yonsei University College of Medicine, discusses findings that showed the use of internal mammary area irradiation (IMNI) in regional nodal irradiation did not significantly improve disease-free survival for women with node-positive breast cancer. However, patients with medially or centrally located tumors may be considered for treatment with IMNI (Abstract 2).

Prostate Cancer

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may benefit patients with localized prostate cancer. Further biomarkers are needed to better personalize treatment intensification (Abstract 8).

Advertisement

Advertisement



Advertisement